Attached files
| file | filename |
|---|---|
| EX-3.1(II) - THIRD AMENDED BYLAWS - Corix Bioscience, Inc. | e31ii.htm |
| EX-3.1(I) - AMENDED ARTICLES - Corix Bioscience, Inc. | e31i.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
DATE OF EARLIEST EVENT REPORTED: October 9, 2017
DATE OF REPORT: October 13, 2017
Corix Bioscience, Inc.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN CHARTER)
| Wyoming | 333-150548 | 75-3265854 | ||
(STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION) |
(COMMISSION FILE NO.) | (IRS EMPLOYEE IDENTIFICATION NO.) |
18662 MacAurther Boulevard, Suite 200 in Irvine, CA 92612
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)
(623) 551-5808
(ISSUER TELEPHONE NUMBER)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting Material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter. ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
| -1- |
SECTION 5 – CORPORATE GOVERNANCE AND MANAGEMENT
Item 5.03 – Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
On October 9, 2017, the State of Wyoming entered the Articles of Amendment filed by Corix Bioscience, Inc., a Wyoming corporation (the “Company”). The Company amended its Articles in order to delete the prior disclosures regarding the Real Estate Committee. The Real Estate Committee was terminated pursuant to the consent of the members of the Real Estate Committee, as allowed for under Article VII, Section 7.6 of the Articles. As a result of the entry of the Articles of Amendment, the Company’s Third Amended Bylaws became effective. The Company’s fiscal year was not revised.
SECTION 9 – FINANCIAL STATEMENTS AND EXHIBITS
(d) Exhibits
| Exhibit No. | Document |
| 3.1(i) | Articles of Amendment |
| 3.1(ii) | Third Amended Bylaws |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
Corix Bioscience, Inc.
By: /s/ Michael Ogburn
Name: Michael Ogburn
Title: Chief Executive Officer and President
Dated: October 16, 2017
| -2- |